/
Oncology
Pancreatic Cancer
357
Pipeline Programs↗
484
Active Trials↗
220
Companies Involved↗
Pancreatic Cancer is a highly competitive landscape with 357 programs across 220 companies. The most active players are Ono Pharmaceutical Co. Ltd, Amplia Therapeutics Limited, Astellas. 40 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical76
Phase 149
Phase 2192
Phase 340
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
272 of 326 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 326 classified programs, each share of the total. Modality classified for 98% of 357 pipeline programs.
Analysis
Trial Status
1,638
clinical trials
Completed687 · 42%
Recruiting244 · 15%
Terminated199 · 12%
Unknown status191 · 12%
Active, not recruiting124 · 8%
Not yet recruiting114 · 7%
Other79 · 5%
Clinical Trials
Trial Activity
1638 trials
Page 1 of 110
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)